Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
Hongbin He, Hua Jiang, Yun Chen, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 614

Showing 1-25 of 614 citing articles:

The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Karen V. Swanson, Meng Deng, Jenny P.‐Y. Ting
Nature reviews. Immunology (2019) Vol. 19, Iss. 8, pp. 477-489
Open Access | Times Cited: 3550
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Tao Gong, Lei Liu, Wei Jiang, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 2, pp. 95-112
Closed Access | Times Cited: 1295
Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors
Yang Yang, Huanan Wang, Mohammed Kouadir, et al.
Cell Death and Disease (2019) Vol. 10, Iss. 2
Open Access | Times Cited: 1063
Pharmacological Inhibitors of the NLRP3 Inflammasome
Ayesha Zahid, Bofeng Li, Arnaud John Kombe Kombe, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 563
An update on the regulatory mechanisms of NLRP3 inflammasome activation
Seungwha Paik, Jin Kyung Kim, Prashanta Silwal, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 5, pp. 1141-1160
Open Access | Times Cited: 533
NLRP3 and pyroptosis blockers for treating inflammatory diseases
Rebecca C. Coll, Kate Schroder, Pablo Pelegrı́n
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 8, pp. 653-668
Open Access | Times Cited: 441
The Immunomodulatory Metabolite Itaconate Modifies NLRP3 and Inhibits Inflammasome Activation
Alexander Hooftman, Stefano Angiari, Svenja Hester, et al.
Cell Metabolism (2020) Vol. 32, Iss. 3, pp. 468-478.e7
Open Access | Times Cited: 429
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Li Wang, Arthur V. Hauenstein
Molecular Aspects of Medicine (2020) Vol. 76, pp. 100889-100889
Closed Access | Times Cited: 326
The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases
Hallie Blevins, Yiming Xu, Savannah Biby, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 270
Anti-inflammatory activity of curcumin-loaded tetrahedral framework nucleic acids on acute gouty arthritis
Mei Zhang, Xiaolin Zhang, Taoran Tian, et al.
Bioactive Materials (2021) Vol. 8, pp. 368-380
Open Access | Times Cited: 201
Gallic Acid Alleviates Gouty Arthritis by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis Through Enhancing Nrf2 Signaling
Yuqing Lin, Tianyu Luo, Anli Weng, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 199
Programming inflammatory cell death for therapy
Shelbi Christgen, Rebecca E. Tweedell, Thirumala‐Devi Kanneganti
Pharmacology & Therapeutics (2021) Vol. 232, pp. 108010-108010
Open Access | Times Cited: 196
Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF-κB pathways
Huahong Yang, Hongming Lv, Haijun Li, et al.
Cell Communication and Signaling (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 192
NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword
Shaima’a Hamarsheh, Robert Zeiser
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 186
The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease
Kendra L. Hanslik, Tyler K. Ulland
Frontiers in Neurology (2020) Vol. 11
Open Access | Times Cited: 177
Therapeutic modulation of inflammasome pathways
Dhruv Chauhan, Lieselotte Vande Walle, Mohamed Lamkanfi
Immunological Reviews (2020) Vol. 297, Iss. 1, pp. 123-138
Open Access | Times Cited: 173
Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19
Adnan Muhammad Shah
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 169
Perfluoroalkyl substance pollutants activate the innate immune system through the AIM2 inflammasome
Liqiu Wang, Tao Liu, Shuai Yang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 155
Inflammasomes contributing to inflammation in arthritis
Lotte Spel, Fabio Martinon
Immunological Reviews (2020) Vol. 294, Iss. 1, pp. 48-62
Open Access | Times Cited: 152
P2X7 receptor and the NLRP3 inflammasome: Partners in crime
Pablo Pelegrı́n
Biochemical Pharmacology (2020) Vol. 187, pp. 114385-114385
Closed Access | Times Cited: 150
The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
Tao Liang, Yang Zhang, Suyuan Wu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 129
The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies
Ni Zhao, Bin Di, Lili Xu
Cytokine & Growth Factor Reviews (2021) Vol. 61, pp. 2-15
Open Access | Times Cited: 127
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Lieselotte Vande Walle, Mohamed Lamkanfi
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 1, pp. 43-66
Closed Access | Times Cited: 120
Impact of intracellular innate immune receptors on immunometabolism
Wei-Chun Chou, Elena Rampanelli, Xin Li, et al.
Cellular and Molecular Immunology (2021) Vol. 19, Iss. 3, pp. 337-351
Open Access | Times Cited: 113
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor
Yun Chen, Hongbin He, Bolong Lin, et al.
Cellular and Molecular Immunology (2021) Vol. 18, Iss. 6, pp. 1425-1436
Open Access | Times Cited: 107
Page 1 - Next Page

Scroll to top